Researchers at UCSF and Gladstone Institutes have identified a combination of FDA-approved anticancer drugs, letrozole and irinotecan, that reversed Alzheimer’s-related brain degeneration and memory loss in mouse models. The approach was guided by computational analysis of gene expression in human brain cells and electronic health records, supporting a precision medicine strategy for Alzheimer’s. The findings, published in Cell, signal a promising direction for treating this complex neurodegenerative disease.